Archean Chemical Industries

Bromine cost-curve leader

Last close: ₹490.60; 29 Sept 2026 · reference
1D · 1M: +1.6% · +1.3%; price-only
Weight: 0.6%; 31 Jul 2026 · Aug rank —
Thesis review: 8 Sep 2026; Why We Own, p66

Coverage owner: Research (per book); latest results Q Jun-26Screener ↗Tijori ↗NSE ↗

Broker research

No sell-side reports on file

UnavailableUpload broker PDFs to data/research/broker/pdf and run the extraction to add them here.

SWOT

Strengths · Weaknesses · Opportunities · Threats

Draft

Strengths

Bromine cycle turning after three weak years: Q1FY27 bromine realisations +50% YoY, volumes at a five-quarter high; China bromine +35% in Q1CY26 to ~USD 4,900/t (Jun-2026) before easing to USD 4,347/t (Jul-2026) - still far above the 2024-25 trough.
Operating leverage on a low base: FY26 EBITDA Rs 239 cr (22% margin) vs Rs 463 cr (35%) in FY24; ICICI Sec sees >50% EBITDA CAGR FY26-28 as bromine run-rate rises to 20-24 kt and freight/fuel costs stabilise.
New products moving from cost to profit: Acume bromine derivatives EBITDA-positive for the first time in Q1FY27 (Rs 1.9 cr vs Rs -2.7 cr), SOP phase-2 trials by Q3FY27, zinc-bromide off-grid storage.
Optionality in SiC semiconductors: USD 250 mn SiCSem fab in Odisha under ISM fiscal support (agreement 11-May-2026), 60,000 wafers/yr, revenue from FY29 - not in broker estimates.

Weaknesses

vs Tata Chemicals: Tata Chemicals posted a Rs 1,715 cr FY26 loss, ROE 1.3%, Rs 8,001 cr debt and Q1FY27 PAT -81%; soda-ash oversupply from China is structural, whereas Archean's bromine is recovering with a clean balance sheet.
vs GHCL: GHCL is cheap (8.8x, 2.75% yield, ROE 13%, net debt ~nil) but is a soda-ash commodity play with Q1FY27 sales/profit -4% and promoter holding of only 19.8%; Archean offers higher growth (ICICI Sec >50% EBITDA CAGR) and 53% promoter skin-in-the-game.

Opportunities

Q2FY27 results (Nov-2026): bromine volume run-rate progressing toward 20-24 kt and salt pricing stabilisation guided for H2FY27.
SOP phase-2 commissioning by Q3FY27 and continued Acume derivatives profitability.
SiCSem fab milestones (equipment orders with Aixtron, Clas-SiC integration) and any ISM disbursement news.

Threats

Bromine price volatility: prices already fell 11% QoQ in Jul-2026 as Chinese supply recovered; FY26 bromine revenue fell 13% and Q4FY26 had technical downtime.
Capital intensity and execution: borrowings up from Rs 98 cr (FY24) to Rs 466 cr (FY26) funding SOP, derivatives and the USD 250 mn SiC fab - a technology the company has no track record in; interest/depreciation already dragged Q1FY27 PAT -25%.
Salt business (66% of FY26 revenue) faces weak pricing and freight sensitivity; ROE only 5.4% in FY26 (3-yr 11%).

Compiled from the approved one-pager (Why We Own What We Own, 8 Sep 2026): why-we-own → strengths, catalysts → opportunities, key risks → threats, peer caveats → weaknesses. Editorial mapping pending review. · author: compiled from the approved one-pager

Research reports · upload with a check step

0 approved · 0 pending · 0 rejected

Only approved reports are readable from the company page; the reviewer must differ from the uploader. Files are hashed (duplicates skipped) and held in the private store.

Internal evidence

Buoyant sources for this name

August 2026 top-30 disclosure — rank n/a, Chemicals, —. Buoyant AIF I Top 30 Holdings - Aug 2026.pdf
One-pager, "Why We Own What We Own" — p66, 8 Sep 2026. Buoyant_Why_We_Own_What_We_Own_Sep2026.pdf (portfolio as of 31 July 2026)
Sales playbook, Aug 2026 — holdings matrix (PMS/AIF I/AIF II, $31 Jul 2026). Buoyant_Capital_Sales_Playbook_Aug_2026_Full_Holdings.pdf

Original PDFs are in the supplied package on disk; private object storage is not configured, so source pages are referenced, not served.

Company filings

Investor documents (Tijori knowledge base)

annual reports

investor presentations

conference calls

Links open the issuer's or exchange's document; fetched only through the user's browser, never by the platform.

Ownership

Shareholding · Jun'26

Promoter	53.43%
Indian Promoters	53.43%
Chemikas Speciality LLP	30.53%
Pendurthi Ranjit	22.90%
Pendurthi Ravi	0.00%
Public Shareholding	46.57%
Institutions	35.06%
Sbi Small Cap Fund	6.88%
Dsp Small Cap Fund	3.06%
Hdfc Mutual Fund - Hdfc Multi Cap Fund	3.00%
Goldman Sachs Funds - Goldman Sachs India Equity Portfolio	2.46%
Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund	1.11%
Tata Aia Life Insurance Co Ltd-Whole Life Mid Cap Equity Fund-Ulif 009 04/01/07 Wle 110	1.06%
Icici Lombard General Insurance Company Ltd	1.06%